DesignCon: FPGA caveman lag in tools
Mark LaPedus, EETimes
2/1/2011 9:31 PM EST
SANTA CLARA, Calif. - FPGA vendors continue to keep pace with Moore’s Law.
Altera Corp. and Xilinx Inc. have separately announced new and complex 28-nm devices. Intel Corp. will lend its semiconductor process technology muscle to build FPGAs for programmable logic startup Achronix Semiconductor Corp. at 22-nm and beyond under the terms of a recent agreement between the two companies.
But with each new family, the gap between traditional design tools and the underlying silicon capabilities is expanding. Designers are frustrated by inefficient and tedious design tools. Major categories of challenges that designers face include verification, debug and integration with PCBs.
|
|
E-mail This Article |
|
Printer-Friendly Page |
Related News
- QuickLogic Announces New Aurora™ FPGA/eFPGA User Tools with Enhancements for Reconfigurable Computing
- Microchip Slashes Time to Innovation with Industry's Most Power-Efficient Mid-Range FPGA Industrial Edge Stack, More Core Library IP and Conversion Tools
- Rapid Silicon's Raptor Software Out-Performs All EDA Tools in the Industry
- CHIPS Alliance Forms F4PGA Workgroup to Accelerate Adoption of Open Source FPGA Tooling
- Lattice Semiconductor and Synopsys Renew Partnership on FPGA Synthesis Tools
Breaking News
- RISC-V International Promotes Andrea Gallo to CEO
- See the 2025 Best Edge AI Processor IP at the Embedded Vision Summit
- Andes Technology Showcases RISC-V AI Leadership at RISC-V Summit Europe 2025
- RISC-V Royalty-Driven Revenue to Exceed License Revenue by 2027
- Keysom Unveils Keysom Core Explorer V1.0
Most Popular
- RISC-V International Promotes Andrea Gallo to CEO
- See the 2025 Best Edge AI Processor IP at the Embedded Vision Summit
- Andes Technology Showcases RISC-V AI Leadership at RISC-V Summit Europe 2025
- Ceva, Inc. Announces First Quarter 2025 Financial Results
- Cadence Unveils Millennium M2000 Supercomputer with NVIDIA Blackwell Systems to Transform AI-Driven Silicon, Systems and Drug Design






